LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
15.76
+0.11 (0.70%)
Oct 30, 2025, 9:40 AM EDT - Market open
Company Description
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
LB Pharmaceuticals Inc
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 11, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Heather Turner |
Contact Details
Address: One Pennsylvania Plaza, Suite 1025 New York, New York 10119 United States | |
| Phone | 212 605 0300 |
| Website | lbpharma.us |
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001691082 |
| CUSIP Number | 50180M108 |
| ISIN Number | US50180M1080 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 17, 2025 | SCHEDULE 13G | Filing |
| Sep 25, 2025 | SCHEDULE 13D | Filing |
| Sep 19, 2025 | SCHEDULE 13G | Filing |
| Sep 19, 2025 | SCHEDULE 13D | Filing |
| Sep 18, 2025 | SCHEDULE 13G | Filing |
| Sep 18, 2025 | SCHEDULE 13G | Filing |
| Sep 12, 2025 | 8-K | Current Report |
| Sep 12, 2025 | 424B4 | Prospectus |
| Sep 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 10, 2025 | EFFECT | Notice of Effectiveness |